mart-1, gp100, tyrosinase peptides
Vaccineexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 1997 (NCT00001685)
Timeline
1990s
- Jan 1, 1997
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- TyrosinaseImmunity, active
TYR immunity, active
- Melanocyte protein PMELImmunity, active
PMEL immunity, active
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mart-1, gp100, tyrosinase peptides
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00001685 | Phase 2 | Nov 1, 1997 | National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 1997 |
1 organizations
Page 1 / 1